Screener
AbCellera Biologics Inc. ABCL Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s deferred revenue?
- AbCellera Biologics Inc. (ABCL) reported deferred revenue of $20.71M in Q2 2026.
- How has AbCellera Biologics Inc.'s deferred revenue changed year-over-year?
- AbCellera Biologics Inc.'s deferred revenue increased by 22.2% year-over-year, from $16.95M to $20.71M.
- What is the long-term trend for AbCellera Biologics Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s deferred revenue has grown at a 15.5% compound annual growth rate (CAGR), from $6.59M to $13.53M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about AbCellera Biologics Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude